AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
ApexOnco Front Page
Recent articles
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
Yet more data validate B7-H3, and put MediLink in the deal-making frame.
The group’s cancer focus is a TROP2 ADC it reckons could have a safety and efficacy edge.
Gilead links up with Tubulis, while GSK taps BioNTech’s partner DualityBio.
Phase 3 development plans for BNT327 and ivonescimab start to diverge.
The US subsidiary of South Korea’s HLB will take on the selective FGFR2 inhibitor.
Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.
